Compound class:
Synthetic organic
Comment: CDRI-97/78 is a novel trioxane peroxide with promising antimalarial activity [2]. It is a simplified analogue of artemisinin and retains the crucial endoperoxide bridge.
|
|
No information available. |
Summary of Clinical Use |
CDRI-97/78 has completed a first-in-human Phase 1 clinical trial and found to be well tolerated in healthy volunteers [1]. |